Dr. Paul Tooney - Selected Publications
Tooney, P.A., Sakai, T, Sakia, K. and Mosher, D.F. (1998). Restricted localization of Thrombospondin-2 protein during mouse embryogenesis: A comparison to Thrombospondin-1. Matrix Biology 17:131-143.
This was the first description of the localisation of TSP2 protein during embryogenesis.
Bowden, NA, Weidenhofer, J, Scott, RJ., Schall, U, Todd, J. Michie, PT, and Tooney, PA. (2006) Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophrenia Research 82: 175-183.
This paper showed for the first time that gene expression profiling has the ability to identify subtypes of schizophrenia.
Weidenhofer, J. Bowden, NA, Scott, RJ and Tooney, PA. (2006) Altered Gene Expression in the Amygdala in Schizophrenia: Up-regulation of Genes Located in the Cytomatrix Active Zone. Mol. Cell. Neurosci. 31: 243-250.
This paper reported the most extensive analysis of gene expression in the amygdala identifying new potential schizophrenia-susceptibility genes
Tooney, P.A., Crawter, V.C. and Chahl, L.A. 2001. Increased tachykinin NK1 receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol Psychiatry 49: 523-527.
This was a novel finding in the field of schizophrenia research implicating the tachykinin NK1 receptor in this disorder.
- Australian Postgraduate Research Award (1991-1993)
- Invited speaker – Australasian Society for Biological Psychiatry meeting, Melbourne December 2001.
- Invited to give an oral presentation at the International Congress on Schizophrenia Research, BA, Canada, May 2001.
- Invited Speaker - Australian Physiological and Pharmacological Society meeting, University of Newcastle, Sept. 1999
- Dr. Tooney has a keen interest in understanding the cellular and molecular mechanisms of diseases, so that better diagnoses and treatment strategies can be developed. Since 1998 Dr. Tooney has focused on schizophrenia and established a program of research to investigate the genetics schizophrenia to develop a biological basis for diagnosis, further the understanding of the molecular changes in schizophrenia and identify new drug targets. Dr. Tooney has published 6 peer-reviewed papers in the field of schizophrenia and is a chief investigator on successful external funding applications totalling over $0.5 million (ARC Lief, Australian Rotary Health Research Fund, HMRI). Dr Tooney co-supervised one honours student (First Class; 2004) and currently co-supervises three PhD students (two submitted their theses in January 2006) and two honours students.